FDA approves expanded indication for FoundationOneCDx as a companion diagnostic for Lynparza

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved FoundationOneCDx to be used as a companion diagnostic for Lynparza (Olaparib) for first line maintenance therapy in BRCA-mutated advanced ovarian cancer.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login